What vaginal estrogen treats
After menopause, lower estrogen thins and dries the tissues of the vagina, vulva and lower urinary tract. The result, called genitourinary syndrome of menopause (GSM), can mean dryness, burning, pain with sex, urgency and repeat urinary infections. The Menopause Society estimates GSM affects about 27% to 84% of postmenopausal women and is likely underdiagnosed and undertreated (NAMS GSM statement 2020, PMID: 32852449).
Low-dose vaginal estrogen treats the tissue directly. The Menopause Society recommends it (or other options such as vaginal DHEA or oral ospemifene) when over-the-counter moisturizers and lubricants are not enough, and notes the low-dose products cause minimal absorption into the blood (NAMS 2022, PMID: 35797481; NAMS GSM statement 2020, PMID: 32852449).
This article is general information, not medical advice or a dosing recommendation. Decisions about starting, changing or stopping a prescription belong with a licensed clinician who knows your history.
The forms and what trials show
| Form | Typical use | FDA-approved examples |
|---|---|---|
| Cream | Applied with an applicator or fingertip | Estradiol cream (Estrace), conjugated estrogens cream (Premarin) |
| Tablet or insert | Small tablet or softgel placed in the vagina | Estradiol vaginal inserts (Vagifem and generics, Imvexxy) |
| Low-dose ring | Soft ring left in place for 3 months | Estring |
A Cochrane review of 30 randomized trials (6,235 women) found no evidence of a difference in symptom relief between the ring, tablets and creams; each improved symptoms compared with placebo, although the overall evidence quality was low to moderate. Creams were associated with more endometrial thickening than the ring in two trials, possibly because higher cream doses were used (Lethaby et al., Cochrane 2016, PMID: 27577677).
For repeat urinary tract infections after menopause, a Cochrane review found that vaginal estrogen reduced infections in two small placebo-controlled trials, while oral estrogen did not (Perrotta et al., Cochrane 2008, PMID: 18425910).
Femring is also a vaginal ring, but it is a higher-dose systemic product for hot flashes, not a low-dose GSM treatment. Systemic forms are covered in estrogen patch vs gel vs pill.
Long-term safety data
Two large cohorts followed vaginal estrogen users who were not taking systemic hormones:
• Women’s Health Initiative Observational Study: 45,663 women followed for a median 7.2 years. In women with a uterus, rates of stroke, invasive breast cancer, colorectal cancer, endometrial cancer and blood clots did not differ significantly between users and non-users (Crandall et al., Menopause 2018, PMID: 28816933).
• Nurses’ Health Study: over 18 years of follow-up, vaginal estrogen use was not associated with a higher risk of cardiovascular disease, cancer or hip fracture (Bhupathiraju et al., Menopause 2019, PMID: 30562320).
Both are observational, so they show no signal of harm rather than proving safety. The Menopause Society says a progestogen is generally not needed with low-dose vaginal estrogen, while noting that trial data on the uterine lining beyond 1 year are lacking (NAMS 2022).
The 2026 label change
For years, low-dose vaginal products carried the same boxed warning as systemic hormone therapy. Members of a July 2025 FDA expert panel highlighted the adverse effects of that class labeling, especially for local vaginal estrogen (Pinkerton et al., Menopause 2026, PMID: 42084927). On February 12, 2026 the FDA approved Estring’s updated label as the first vaginal estrogen in a batch of six products whose boxed warnings on cardiovascular disease, breast cancer and dementia were removed (FDA). Estring’s current label carries no boxed warning and is indicated for moderate to severe symptoms of vulvar and vaginal atrophy due to menopause (DailyMed). Other vaginal products are being updated in later batches.
After breast cancer
This is where caution remains. The American College of Obstetricians and Gynecologists says non-hormonal approaches come first for people with a history of estrogen-dependent breast cancer, that vaginal estrogen should be reserved for those whose symptoms do not respond, and that the decision should be made with the oncologist. It also states that available data do not show a higher recurrence risk with vaginal estrogen (ACOG Committee Opinion 659, PMID: 26901334).
The Menopause Society adds that the conversation matters most for people on aromatase inhibitors, whose estrogen levels are deliberately suppressed (NAMS 2022).
Safety: what to report
• Any vaginal bleeding after menopause needs prompt evaluation before treatment and if it appears during treatment.
• Possible side effects in trials included breast tenderness, spotting, discharge, and vaginal irritation, burning or itching (Perrotta et al., Cochrane 2008).
• Tell your clinician if you have had breast or endometrial cancer, blood clots, or liver disease before starting.
This article is general information, not medical advice or a dosing recommendation. Decisions about starting, changing or stopping a prescription belong with a licensed clinician who knows your history.
Cost and online options
Generic estradiol cream and inserts are among the least expensive prescriptions in women’s health; current prices and online options are on vaginal estrogen online. To compare menopause programs, see our women’s HRT comparison and online menopause HRT compared.
Disclosure
CalcMyPeptide may earn commissions from some telehealth providers on our comparison and review pages, which list only vetted providers whose affiliate programs have approved us or are reviewing our application. This article contains no paid links. How we rank providers and get paid: telehealth disclosure and methodology.